Skip to content

Evaluating the Impact of Transcendental Meditation on Trauma Symptoms, Depression, Anxiety, and Sleep Problems Among Israeli Civilians Post-October 7, 2023: A Pilot Study.

Ofra Walter, Sanford Nidich, Kimia Shahrokhi

Journal of Clinical Psychology June 29, 2026 DOI: 10.1002/jclp.70172 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pilot study Randomized Peer reviewed
Sample size 39
Population Israeli civilians evacuated after October 7, 2023
Intervention Transcendental meditation
Duration 8-week intervention
Topics Anxiety Depression Meditation
Keywords Israeli–palestinian conflict Civilian evacuations Displaced populations Mental health interventions Psychological resilience Stress management Transcendental meditation tm War trauma
Key points Participation in transcendental meditation was associated with statistically significant decreases in PTSD symptoms, depression, anxiety, and sleep problems among trauma-exposed civilians.

Abstract

The mass evacuation of Israeli residents from conflict zones after the events of October 7, 2023, coupled with ongoing security threats, has taken a substantial psychological toll, with many individuals exhibiting symptoms of post-traumatic stress disorder (PTSD), anxiety, and sleep problems. This pilot study examined the feasibility and preliminary within-group changes associated with participation in transcendental meditation (TM), a non-pharmacological program, in relation to PTSD symptoms, depression, anxiety, and sleep problems among 39 Israeli civilians evacuated after October 7. In an 8-week intervention, we examined changes in psychological well-being using the PTSD Checklist for DSM-5 (PCL-5), Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder scale (GAD-7), and Insomnia Severity Index (ISI). Changes in PTSD symptoms, depression symptoms, anxiety, and sleep problems were analyzed using dependent t-tests. Additional analyses of baseline, 4-week, and 8-week post-test data used repeated-measures analysis of variance. Participants showed statistically significant within-group decreases from baseline to post-test in PTSD symptoms, depression, anxiety, and sleep problems. Findings provide preliminary support for the feasibility and acceptability of TM in trauma-exposed civilians and suggest that participation in the program was associated with improvements in psychological symptoms over time. Given the uncontrolled pilot design, these results should be interpreted cautiously and require confirmation in randomized controlled trials.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Citations in the library

Explore topics